CN104206595A - 一种降脂降糖的地骨皮保健茶及其制备方法 - Google Patents
一种降脂降糖的地骨皮保健茶及其制备方法 Download PDFInfo
- Publication number
- CN104206595A CN104206595A CN201410425687.3A CN201410425687A CN104206595A CN 104206595 A CN104206595 A CN 104206595A CN 201410425687 A CN201410425687 A CN 201410425687A CN 104206595 A CN104206595 A CN 104206595A
- Authority
- CN
- China
- Prior art keywords
- parts
- root bark
- root
- berry
- chinese wolf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 claims abstract description 126
- 210000004369 blood Anatomy 0.000 claims abstract description 123
- 244000241872 Lycium chinense Species 0.000 claims abstract description 97
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 97
- 230000036541 health Effects 0.000 claims abstract description 39
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 34
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 27
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 240000000249 Morus alba Species 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 19
- 230000001603 reducing effect Effects 0.000 claims abstract description 15
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 14
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 44
- 241001122767 Theaceae Species 0.000 claims description 28
- 235000013616 tea Nutrition 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 20
- 230000008901 benefit Effects 0.000 claims description 19
- 244000197580 Poria cocos Species 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 244000241838 Lycium barbarum Species 0.000 claims description 16
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 16
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 15
- 240000007164 Salvia officinalis Species 0.000 claims description 15
- 235000005412 red sage Nutrition 0.000 claims description 15
- 241001643642 Viticis Species 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 14
- 241000112528 Ligusticum striatum Species 0.000 claims description 13
- 241000488974 Loranthus Species 0.000 claims description 13
- 241000218231 Moraceae Species 0.000 claims description 13
- 230000003071 parasitic effect Effects 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000012535 impurity Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 235000013372 meat Nutrition 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 241000241413 Propolis Species 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 229940069949 propolis Drugs 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000005057 refrigeration Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
- 230000006870 function Effects 0.000 abstract description 16
- 235000009508 confectionery Nutrition 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 15
- 235000019640 taste Nutrition 0.000 abstract description 12
- 230000036772 blood pressure Effects 0.000 abstract description 9
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 230000000903 blocking effect Effects 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 4
- 150000002357 guanidines Chemical class 0.000 abstract description 4
- 230000027939 micturition Effects 0.000 abstract description 4
- 239000003205 fragrance Substances 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract 2
- 241000234276 Curculigo Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241000316332 Scurrula Species 0.000 abstract 1
- 241000915604 Scutellaria barbata Species 0.000 abstract 1
- 206010047141 Vasodilatation Diseases 0.000 abstract 1
- 235000001667 Vitex agnus castus Nutrition 0.000 abstract 1
- 244000063464 Vitex agnus-castus Species 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 210000001640 nerve ending Anatomy 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 235000019605 sweet taste sensations Nutrition 0.000 abstract 1
- 230000002889 sympathetic effect Effects 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 51
- 206010012601 diabetes mellitus Diseases 0.000 description 44
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 32
- 235000019197 fats Nutrition 0.000 description 29
- 210000003734 kidney Anatomy 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 210000000988 bone and bone Anatomy 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- 230000001077 hypotensive effect Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 13
- 241000736199 Paeonia Species 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 201000005577 familial hyperlipidemia Diseases 0.000 description 12
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 206010037660 Pyrexia Diseases 0.000 description 10
- 208000002173 dizziness Diseases 0.000 description 10
- 230000035922 thirst Effects 0.000 description 10
- 238000005728 strengthening Methods 0.000 description 9
- 208000006820 Arthralgia Diseases 0.000 description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 241000411851 herbal medicine Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 7
- 210000003128 head Anatomy 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 201000001881 impotence Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 208000009205 Tinnitus Diseases 0.000 description 6
- 206010046788 Uterine haemorrhage Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 235000014101 wine Nutrition 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 208000037093 Menstruation Disturbances Diseases 0.000 description 5
- 206010027339 Menstruation irregular Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- 206010049865 Achromotrichia acquired Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 244000301850 Cupressus sempervirens Species 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000003356 anti-rheumatic effect Effects 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 229930183024 Kukoamine Natural products 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- GDQXJMLXEYSICD-UHFFFAOYSA-N cyclomorusin A Chemical compound C1=CC(C)(C)OC2=CC(O)=C(C(=O)C=3C(C=C(C)C)OC=4C(=CC=C(O)C=4)C=3O3)C3=C21 GDQXJMLXEYSICD-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000013118 diabetic mouse model Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 208000003512 furunculosis Diseases 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000021142 long-term diet Nutrition 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 235000016811 Biondella Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- UGWAFWFSLCHCJD-UHFFFAOYSA-N Cornuside Natural products OC1C(O)C(O)C(CO)OC1OC1C(C=C)C(CCOC(=O)C=2C=C(O)C(O)=C(O)C=2)C(C(O)=O)=CO1 UGWAFWFSLCHCJD-UHFFFAOYSA-N 0.000 description 1
- 244000265913 Crataegus laevigata Species 0.000 description 1
- 235000013175 Crataegus laevigata Nutrition 0.000 description 1
- DAYVKEVMSODOPS-UHFFFAOYSA-N Cyclomorusin Natural products CC(=CC1Oc2ccccc2C3=C1C(=O)c4c(O)cc5OC(C)(C)C=Cc5c4O3)C DAYVKEVMSODOPS-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000092728 Eleutherococcus gracilistylus Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 235000015463 Lycium carolinianum Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 229930182734 Sanggenon Natural products 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- SMTKSCGLXONVGL-ZEIULZLQSA-N methyl (2r,3s,4r)-3-ethenyl-4-[2-(3,4,5-trihydroxybenzoyl)oxyethyl]-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2h-pyran-5-carboxylate Chemical compound O([C@H]1OC=C([C@@H]([C@@H]1C=C)CCOC(=O)C=1C=C(O)C(O)=C(O)C=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SMTKSCGLXONVGL-ZEIULZLQSA-N 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019590 thick flavour Nutrition 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种降脂降糖的地骨皮保健茶,其所述地骨皮保健茶包括以下重量份数的原料:地骨皮10~50份,桑寄生10~20份,五加皮10~20份,桑白皮10~20份,山茱萸10~20份,茯苓10~20份,丹参10~20份,川芎10~20份,蔓荆子10~20份,制首乌10~20份,仙茅10~20份,桑葚10~20份,女贞子10~20份,白芍10~20份,虎杖10~20份,半枝莲10~20份。地骨皮饮,治消渴,日夜饮水不止,利小便。现代药理研究:地骨皮含有胍的衍生物,具有降血糖作用。本品还具有降脂、降压作用,其降压作用与中枢神经有关,可能为阻断交感神经末梢而直接舒张血管。本发明清香四溢,微苦甘醇;再加上一些活血化瘀,口感清淡,不破坏地骨皮味甘味道的中药,不影响口感,使人易于接受,能较好的达到提高降糖降脂的功效。
Description
技术领域
本发明涉及含有来源于植物组份的保健品,特别涉及一种降脂降糖的地骨皮保健茶及其制备方法。
背景技术
祖国医学没有高脂血症的病名,但有关高脂血症的症状、病因、病机、治疗等方面的论述在在许多古医籍中有所记载,《黄帝内经》中的“膏人”、“肥人”指的就是血脂过高的肥胖之人。随着人们生活水平的提高,我国冠心病人群的患病率也在不断提高,且患病年龄趋于年轻化,冠心病已成为严重威胁人们生命的杀手。冠心病的主要原因是冠状动脉粥样硬化,动脉粥样硬化也是其它部位动脉病变的主要原因之一。引发动脉硬化的危险因素有很多,例如高脂血症(尤其是高胆固醇血症),糖尿病,高血压,肥胖或超重,吸烟等,其中高胆固醇血症是动脉粥样硬化最重要的危险因素。现代医学最重要的进展之一就是明确了减低血中胆固醇(TC)尤其是LDL.C,可以大幅度降低冠心病病死率。
由于经济的日益发达,现代人生活水平的不断提升,致使人们过多的热爱享受,不注意自己的生活方式、行为习惯、饮食嗜好,从而引起的疾病。快节奏的社会生活,激烈竞争的工作压力,对现代人的身心健康造成了严重的威胁,加上长期的饮食不合理,即:精粮完全取代粗粮,大量的三高(高热、高蛋白、高脂肪)、三多(防腐剂多、增味剂多、激素多)食物的摄入和食物中残留的农药、化肥在体内的存积,再加上空气、水源污染和运动量偏小,肥胖和糖尿病就成了都市一族的富贵病。
糖尿病引起血脂增高的原因是由于糖尿病人胰岛素不足时,体内脂酶活泼性是减低的,因此容易血脂增高。另一方面糖尿病本身除糖代谢紊乱外同时还伴脂肪、蛋白质和水、电介质的紊乱。经常有游离脂肪酸从脂肪库中动员出来,使血中甘油三酯及游离脂肪酸浓度增高。再一方面2型糖尿病人进食过多,运动少,促使体内脂类合成增多,这也是造成血脂增高的原因。而肥胖伴高血脂者,由于胰岛素受体数相对减少,从而产生胰岛素抵抗,易诱发糖尿病。糖尿病是由于胰岛素分泌、胰岛素作用或两者同时存在缺陷所引起的碳水化合物、蛋白质及脂肪代谢紊乱的一种综合征。基本特征是血糖增高,长期损害为各种器官的功能障碍和衰竭,包括不断进展的血管性疾病,即视网膜病变、失明、肾病、肾功能衰竭、神经病变伴足部溃疡、截肢和自主神经功能改变,还有不断增加的心血管、脑血管和周围血管病变的危险。
地骨皮为枸杞的根皮,药肄为干品,性味甘寒,入肺、肝、肾经。《圣济总录》记载,地骨皮饮,治消渴,日夜饮水不止,小便利。日本《医心方》中枸杞汤,治消渴唇干口燥,以本品配石膏、小麦煮汤频服。现代药理研究:地骨皮含有胍的衍生物,具有降血糖作用。《中医药信息》报道:地骨皮对小鼠葡萄糖性及肾上腺素性高血糖有降低作用,对糖尿病模型鼠胰岛β细胞形态结构的损害有一定的减轻作用。此外,本品还具有降脂、降压作用,其降压作用与中枢神经有关,可能为阻断交感神经末梢而直接舒张血管。
地骨皮为茄科植物枸杞或宁夏枸杞的干燥根皮。性味:甘,寒。归肺、肝、肾经。功能凉血,退虚热,泻肺火。适用于阴虚潮热,盗汗,骨蒸;肺热咳嗽;血热妄行的出血证。《神农本草经》记载:“主五内邪气,热中消渴,周痹。”因此,古籍也记载和证实了地骨皮可治消渴病(糖尿病)。
地骨皮的主要成分为:含桂皮酸和多量酚类物质,甜菜碱,尚分离到B一谷甾醇、亚油酸及地骨皮甲素等。正是这些有效的成分可降低“三高”(高血脂、高血压、高血糖)。降血糖过程主要是对胰岛B细胞分泌胰岛素有促进作用。现代药理学也证实,其煎剂口服可使血糖降低,并呈现降低血脂作用。还能降低血压、减慢心律,大剂量可导致房室传导阻滞。现代中医临床也广泛的应用地骨皮治疗糖尿病,水煎代茶频饮,有一定的降糖及降脂效果;如将地骨皮制成4%浓度的水煎液,适当加点白糖,对降血压也有较好的疗效。地骨皮茶降糖降压降脂虽好,但对于外感风寒、脾胃虚寒、便溏、慢性胃炎、心功能不全等疾病的患者要慎用。
《本草纲目》:枸杞之滋益不独子,而根亦不止于退热而已。但根、苗、子之气味稍殊,而主治亦未必无别。盖其苗乃天精,苦甘而凉,上焦心肺客热者宜之;根乃地骨,甘淡而寒,下焦肝肾虚热者宜之,此皆三焦气分之药,所谓热淫于内,泻以甘寒也。至于子则甘平而润,性滋而补,不能退热,止能补肾润肺,生精益气,此乃平补之药,所谓精不足者,补之以味也。分而用之,则各有所主,兼而用之,则一举两得。世人但知用黄芩、黄连苦寒以治上焦之火,黄柏、知母苦寒以治下焦阴火,谓之补阴降火,久服致伤元气,而不知枸杞、地骨,甘寒平补,使精气充而邪火自退之妙,惜哉!予尝以青蒿佐地骨退热,屡有殊功,人所未喻者。《本草汇言》:王绍隆云,骨中火热为眚,煎熬真阴,以地中之骨皮,甘寒清润,不泥不滞,非地黄、白芍同流。《本草正》:地骨皮,枸杞根也,南者苦味轻,微有甘辛,北者大苦性劣,入药惟南者为佳。其性辛寒,善入血分,凡不因风寒而热在精髓阴分者最宜。此物凉而不峻,可理虚劳,气轻而辛,故亦清肺。《药品化义》:地骨皮,外祛无定虚邪,内除有汗骨蒸,上理头风,中去胸胁气,下利大小肠,通能奏效。入泻白散,清金调气,疗肺热有余咳嗽;同养血药,强阴解肌,调疮痘不足皮焦。以其性大寒,酒煎二两,治湿热黄疸最为神效。牡丹皮能去血中热,地骨皮能去气中之热,宜别而用。《本草新编》:地骨皮,非黄柏、知母之可比,地骨皮虽入肾而不凉肾,止入肾而凉骨耳,凉肾必至泄肾而伤胃,凉骨反能益肾而生髓,黄柏、知母泄肾伤胃,故断不可多用以取败也,骨皮益肾生髓,断不可少用而图功。欲退阴虚火动,骨蒸劳热之症,用补阴之药,加地骨皮或五钱或一两,始能凉骨中之髓,而去骨中之热也。
现代人选择一些保健食品或功能食品都是为了强身健体。保健品的功能主要是改善人体血液循环,滋阴补肾,提高人体免疫力。现在市面上出售的各种保健品、药品鱼龙混杂,大多数只是虚假宣传的噱头,有的不仅没有保健成分,还造成人身体的巨大伤害。可是中药气味清苦,很多人不愿长期服用;即使服用,是药三分毒,让人长期服用时也产生抗拒心理。怎么把地骨皮的功效发挥到最大又不伤害人体,并且明显改善口感,使人能接受,是我们迫切需要解决的问题。地骨皮里面含有大量安全有效的活性物质保健品,能大大提高人体免疫力,一直是人们期待解决问题的关键。
发明内容
本发明所要解决的技术问题在于,现在市面上出售的各种保健品、药品鱼龙混杂,大多数只是虚假宣传的噱头,有的不仅没有保健成分,还造成人身体的巨大伤害。中药气味清苦,很多人不愿长期服用;即使服用,是药三分毒,让人长期服用时也产生抗拒心理。地骨皮性味甘寒,入肺、肝、肾经。《圣济总录》记载,地骨皮饮,治消渴,日夜饮水不止,小便利。现代药理研究:地骨皮含有胍的衍生物,具有降血糖作用。本品还具有降脂、降压作用,其降压作用与中枢神经有关,可能为阻断交感神经末梢而直接舒张血管。本发明清香四溢,微苦甘醇;再加上一些活血化瘀,口感清淡,不破坏地骨皮味甘味道的中药,不影响口感,使人易于接受,能较好的达到降糖降脂的功效。
为解决上述技术难题,本发明提供一种降脂降糖的地骨皮保健茶,其所述地骨皮保健茶包括以下重量份数的原料:地骨皮10~50份,桑寄生10~20份,五加皮10~20份,桑白皮10~20份,山茱萸10~20份,茯苓10~20份,丹参10~20份,川芎10~20份,蔓荆子10~20份,制首乌10~20份,仙茅10~20份,桑葚10~20份,女贞子10~20份,白芍10~20份,虎杖10~20份,半枝莲10~20份。
所述降脂降糖的地骨皮保健茶,其所述地骨皮保健茶中各种原料的重量份数可以为:地骨皮10~30份,桑寄生10~15份,五加皮10~15份,桑白皮10~15份,山茱萸10~15份,茯苓10~15份,丹参10~15份,川芎10~15份,蔓荆子10~20份,制首乌10~20份,仙茅10~20份,桑葚10~20份,女贞子10~20份,白芍10~20份,虎杖10~20份,半枝莲10~20份。
所述降脂降糖的地骨皮保健茶,其所述地骨皮保健茶中各种原料的重量份数也可以为:地骨皮10~40份,桑寄生10~20份,五加皮10~20份,桑白皮10~20份,山茱萸10~20份,茯苓10~20份,丹参10~20份,川芎10~20份,蔓荆子10~15份,制首乌10~15份,仙茅10~15份,桑葚10~15份,女贞子10~15份,白芍10~15份,虎杖10~15份,半枝莲10~15份。
为解决上述技术问题,本发明还提供一种降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述地骨皮保健茶的制备步骤包括以下方面:
a.地骨皮的制备;
b.将所述其余原料浸泡乙醇中加热提取成浸膏;
c.再将其余原料提取的浸膏浓缩成颗粒剂、粉剂或膏剂;
d.将浓缩的颗粒剂、粉剂或膏剂与制备好的地骨皮混合,灭菌制备成保健茶剂;
所述步骤a中,在早春、晚秋采挖枸杞树根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟。
所述步骤b中,可以取其余原料洗净去杂,加入占其质量5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用。
所述步骤c中,可以将上述步骤得到的浸膏置入双效真空浓缩器中,浓缩至80℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.5g生药量;浓缩后的膏剂加蜂蜜调和制成颗粒剂;或直接干燥制成粉剂。
所述步骤d中,可以将制好的地骨皮与提炼的其他原料的颗粒剂、粉剂或膏剂混合,经紫外线消毒杀菌后装袋。
为解决上述技术问题,本发明再提供一种降脂降糖的地骨皮保健茶的制备方法,其制备步骤还可以为:
a.地骨皮的制备,作为组分1;
b.将所述其余原料药提取作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂胶或糊精调和制粒,紫外线消毒杀菌后装瓶。
所述步骤a中,早春、晚秋采挖枸杞树根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟;将炒好的地骨皮泡入乙醇中1-2天后,加热提取2次,每次1-2小时,去上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用,成组分1;所述步骤b中,将其余原料药材混合,将其余原料放入占其质量10倍量的乙醇中浸泡24小时以上,加热回流提取2次,每次1~2小时,将2次提取液合并静置;再将上述乙醇提取过的药材的药渣加占其质量10倍量的水加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,作为组分2;所述步骤c中,混合组分1和组分2,回收乙醇后减压放入浓缩器中浓缩,将所得浓缩液调整比重到1.46,减压,浓缩后的膏剂加蜂胶或糊精调和制粒,紫外线消毒杀菌后装瓶。
本发明有益的技术效果在于,地骨皮性味甘寒,入肺、肝、肾经。《圣济总录》记载,地骨皮饮,治消渴,日夜饮水不止,小便利。现代药理研究:地骨皮含有胍的衍生物,具有降血糖作用。本品还具有降脂、降压作用,其降压作用与中枢神经有关,可能为阻断交感神经末梢而直接舒张血管。本发明微苦甘醇;再加上一些活血化瘀,口感清淡,不破坏地骨皮味甘味道的中药,不影响口感,使人易于接受,能较好的达到降糖降脂的功效。没有难闻难以下咽的中药味,使人易于接受,可以明显提高免疫力,中药降糖降脂,具有无毒、能被生物体完全吸收的优点,是我们研究的主要方向。
具体实施方式
在中国人的十大死亡原因中,与代谢疾病相关的死亡率就高达35.7%,与“三高”相关的死亡人数也占总死亡人数的27%。高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。世界卫生组织曾经明确提出,防止心血管病的第一道防线就是减少“三高”和控制“三高”。很多糖尿病人都伴有高脂血症,因此人们通常把糖尿病与高脂血症称为姐妹病,并认为高血脂是糖尿病的继发症。据统计大约40%的糖尿病病人有脂代谢紊乱。其特点是甘油三酯增高和高密度脂蛋白降低。糖尿病引起血脂增高的原因是由于糖尿病人胰岛素不足时,体内脂酶活泼性是减低的,因此容易血脂增高。另一方面糖尿病本身除糖代谢紊乱外同时还伴脂肪、蛋白质和水、电介质的紊乱。经常有游离脂肪酸从脂肪库中动员出来,使血中甘油三酯及游离脂肪酸浓度增高。再一方面2型糖尿病人进食过多,运动少,促使体内脂类合成增多,这也是造成血脂增高的原因。而肥胖伴高血脂者,由于胰岛素受体数相对减少,从而产生胰岛素抵抗,易诱发糖尿病。血脂增高者还易引起心、脑血管并发症。
由于经济的日益发达,现代人生活水平的不断提升,致使人们过多的热爱享受,不注意自己的生活方式、行为习惯、饮食嗜好,从而引起的疾病。快节奏的社会生活,激烈竞争的工作压力,对现代人的身心健康造成了严重的威胁,使半数以上的人处于亚健康状态,表现为:头晕、心慌、乏力、食欲不振、记忆力减退、失眠、对事无兴趣等,加之,长期的饮食不合理,即:精粮完全取代粗粮,大量的三高(高热、高蛋白、高脂肪)、三多(防腐剂多、增味剂多、激素多)食物的摄入和食物中残留的农药、化肥在体内的存积,再加上空气、水源污染和运动量偏小,这样长期下去会使三高症(高血压、高血糖、高血脂)、心脑血管疾病、癌症等所谓的“现代文明病”急速上升,而且不断年轻化,严重的危害到人类的健康和生命。各种原因使免疫系统不能正常发挥保护作用,在此情况下,极易招致细菌、病毒、真菌等感染,因此免疫力低下最直接的表现就是容易生病。
实验证明
1、地骨皮对心血管系统的作用:用地骨皮的浸剂、酊剂及煎剂给麻醉犬、猫、兔静脉注射均有明显的降压作用,并伴有心率减慢和呼吸加快;给不麻醉大鼠灌胃亦有明显降压作用.地骨皮注射剂给麻醉犬静脉注射0.375g/kg能使其血压下降至零而死亡,小剂量重复注射未见快速耐受现象.地骨皮甲醇提取物给大鼠静脉注射0。5g(生药)/kg亦有明显降压活性.地骨皮降压期间,心电图可见心率减慢,P-R间期延长、T波减低,中毒剂量可使豚鼠心脏产生房室传导的部分性乃至完全性阻滞.地骨皮的降压作用除有中枢参与外,还可能与其阻断交感神经末梢及直接舒张血管的作用有关.此外,枸杞素A和枸杞素B有抗肾上腺皮质激素和肾素的作用,亦为其降压作用机制之一.
2、降血糖和降血脂作用:给家兔灌服地骨皮煎剂,先使血糖短时间升高,然后持久降低,4~8小时后尚未恢复.对于注射肾上腺素引起的高血糖并无明显对抗作用,但可缩短高血糖维持时间.家兔皮下注射地骨皮浸膏,亦可使血糖降低.地骨皮水煎剂对四氧嘧啶糖尿病小鼠胰岛B细胞的形态结构损害有一定的减轻作用.地骨皮浸膏灌胃,能使实验性家兔血清总胆固醇含量下降,但对甘油三酯含量影响不大,对肝脏脂肪含量亦无明显影响.甜菜碱则有抗脂肪肝作用。
3、抗病原微生物作用:地骨皮煎剂对伤寒杆菌、甲型副伤寒杆菌与弗氏痢疾杆菌有较强的抑制作用,但对金黄色葡萄球菌无作用;对流感亚洲甲型京科68-1病毒株有抑制其细胞病变作用;对结核杆菌为低效抑菌药物。
4、解热作用:地骨皮水提取物、乙醇提取物及乙醚残渣水提取物灌服或注射对人工发热家兔有显著退热作用。其乙醚提取物及乙醇提取后残渣之水提取物并无作用.其解热作用比氨基比林弱,约与其他解热药相等。
5、其他作用:地骨皮水煎剂对正常小鼠脾细胞产生白细胞介素-2有抑制作用;对环磷酰胺所致小鼠脾细胞白细胞介素-2产生降低有显著提高增强作用;对硫唑嘌呤所致白细胞介素-2产生超常有抑制作用。地骨皮注射剂(100%)对未孕大鼠和小鼠离体子宫有显著兴奋作用。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
山茱萸味酸、涩性,微温。归肝、肾经。补益肝肾,涩精固脱。用于眩晕耳鸣,腰膝酸痛,阳痿遗精,遗尿尿频,崩漏带下,大汗虚脱,内热消渴,为固涩药,它含有山茱萸甙、莫罗甙、7-O-甲基莫罗甙、山茱萸新甙、当药甙、番木鳖甙等环烯醚萜甙类及皂甙、熊果酸、酒石酸、没食子酸、苹果酸、山茱萸鞣质1、2、3等多种有效成份。有明显的利尿、降脂、抗菌与升高血液白细胞的作用,对治疗肝肾亏损所致的眩晕耳鸣、腰酸等症及由于肾阴不足所致的遗精、尿频等症有明显疗效。又因其具有收敛止血功效被常用于妇女体虚所致的月经过多,崩漏带下等症,对男科、妇科的常见病均有很好的治疗作用,大量用于补益药物的生产,故被列为国药四十种大宗品种之一,在中医药界有着广泛的市场。
中药何首乌有生首乌与制首乌之分,直接切片入药为生首乌,用黑豆煮汁拌蒸后晒干入药为制首乌。二者的功用有所不同:生首乌功能解毒、消痈、润肠通便,常用于治疗瘰疬疮痈、风疹瘙痒、肠燥便秘;制首乌功能补肝肾、益精血、乌须发、强筋骨,用于血虚萎黄、眩晕耳鸣、须发早白、腰膝酸软、肢体麻木、崩漏带下、久疟体虚等。本发明所采用的制首乌是补肾益肾的佳品。
桑寄生苦;甘;性平。有祛风湿,益肝肾,强筋骨,安胎的功效。入心、肾二经。功能主治:补肝肾;强筋骨;祛风湿;安胎。主腰膝酸痛;筋骨痿弱;肢体偏枯;风湿痹痛;头错目眩;胎动不安,崩漏下血。用于风湿痹痛,腰膝酸软,筋骨无力,崩漏经多,妊娠漏血,胎动不安;高血压。
五加皮为五加科落叶小灌木细柱五加的干燥的根皮。又名白刺、目骨、追风使、南五加皮等。主产于湖北、湖南、河南、安徽、四川等地。中药五加皮具有祛风湿,补肝肾,强筋骨等功效。《本草纲目》中记载:“补中益气、治风湿痿痹、壮筋骨。”现代研究,本品还具有抗肿瘤、抗疲劳、降低全血粘度、防止动脉粥样硬化形成等作用。五加皮使用方便,煎汤、入丸、散或浸五加皮酒均可,但阴虚火旺者慎用。
仙茅具有补肾助阳、益精血、强筋骨和行血消肿的作用,主要用于肾阳不足、阳痿遗精、虚痨内伤和筋骨疼痛等病症。补肾阳,强筋骨,散寒湿。治阳萎精冷,小便失禁,崩漏,心腹冷痛,腰脚冷痹,痈疽,瘰疬,阳虚冷泻。阳痿精寒,腰膝风冷,筋骨痿痹等症。古方中有仙茅丸,能壮筋骨、益精神、明目、黑须发。《海药本草》:主风,补暖腰脚,清安五脏,强筋骨,消食。宣而复补,主丈夫七伤,明耳目,益筋力,填骨髓,益阳。《日华子本草》:治一切风气,补五劳七伤,开胃下气。
白芍性凉,味苦酸,微寒,具有补血柔肝、平肝止痛。敛阴收汗等功效,适用于阴虚发热、月经不调、胸腹胁肋疼痛、四肢挛急,泻痢腹痛、自汗盗汗、崩漏、带下等症。芍药甙有抗菌、解热、抗炎、增加冠状动脉流量、改善心肌营养血流、扩张血管、对抗急性心肌缺血、抑制血小板聚集、镇静、镇痛、解痉、抗溃疡、调节血糖的作用。白芍煎剂能抑制痢疾杆菌、肺炎链球菌、大肠杆菌、伤寒杆菌、溶血性链球菌、绿脓杆菌等。血虚阴虚、胸腹胁肋疼痛、肝区痛、胆囊炎、胆结石疼痛、泻痢腹痛、妇女行经腹痛、自汗易汗盗汗、腓肠肌痉挛、四肢拘挛疼痛、不安腿综合症等病症患者适宜食用。
虎杖清热解毒,利胆退黄,祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,产后瘀血不下,癓瘕,咳嗽痰多,水火烫伤,跌打损伤,痈肿疮毒。虎杖含有蓼甙、有机酸、葡萄糖甙、多糖类等。有清热解毒、清凉解暑、健胃清食作用,是一种蓼科植物。
半枝莲味辛;苦;性寒。归肺经;肝经;肾经。功能:清热,解毒,散瘀,止血,利尿消肿,定痛。治吐血,衄血,血淋,赤痢,黄疸,咽喉疼痛,肺痈,疔疮,瘰疬,疮毒,癌肿,跌打刀伤,蛇咬伤。《泉州本草》:清热,解毒,法风,散血,行气,利水,通络,破瘀,止痛。内服主血淋,吐血,衄血;外用冶毒蛇咬伤,痈疽,疔疮,无名肿毒。广州部队《常用中草药手册》:清热解毒。治癌见到改善症状的效果;阑尾炎,肝炎。
川芎入肝、脾、三焦三经。功用主治行气开郁,法风燥湿,活血止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《纲目》载:″燥湿,止泻痢,行气开郁。″川芎嗪解除血管平滑肌(主动脉条)痉挛(肾上腺素、氯化钾引起)。还能扩张冠状血管,增加冠脉血流量。对抗垂体后叶素引起的心肌缺血缺氧。减轻结扎冠脉引起的心肌梗死病变程度。
蔓荆子蔓荆子拉丁学名:FRUCTUS VITICIS。用于风热感冒,头痛头风。本品辛能散风,微寒清热,轻浮上行,主散头面之邪,有祛风止痛之效,用治外感风热,头痛头晕,常与菊花、薄荷等同用,头痛头风常与白蒺藜、川芎、钩藤等同用。用于目赤肿痛,目昏多泪。本品能疏散风热,清利头目,故可用治风热上攻,目赤肿痛,目昏多泪,常配菊花、蝉蜕、龙胆草等同用;本品药性升发,清利头目,与黄芪、党参、白芍等同用,还可用治清阳不升,目生翳障,耳鸣耳聋等症,如益气聪明汤。
女贞子,味甘苦、性凉,归肝肾经,具有滋补肝肾、益阴养血之功。现代医学研究证明,女贞子内含熊果酸、甘露醇、葡萄糖、脂肪油等,有强心、利尿和保肝作用,能使因化疗引起的白细胞下降数量升高,并对金黄色葡萄球菌、大肠杆菌有抑制作用。女贞子中含有齐墩果酸女贞子酸、女贞苷、熊果酸、硬脂酸、油酸、甘露醇、白桦脂醇、磷脂以及糖类如女贞子多糖、阿拉伯糖、葡萄糖等,还含有15种氨基酸,11种微量元素及挥发油等。研究认为女贞子有降血糖及降血脂并有抗动脉粥样硬化作用,还有抗菌、抗病毒作用,女贞子煎剂对金黄色葡萄球菌、福氏痢疾杆菌、伤寒杆菌、绿脓杆菌和大肠杆菌均有抑制作用。对B型腺病毒有中等度抑制作用。升高白细胞:女贞子及其成分制剂对血细胞均有一定影响,它对因化疗所致白细胞下降有升高作用。含女贞子的复方也有升白细胞作用。抗血栓作用:齐墩果酸可加快血小板细胞的流动性,减弱了血小板之间的碰撞,使之不易粘连和聚集,更不易在血管内膜沉积,减缓或防止血栓形成,又可降低脂质内膜的沉积,为防治老年人的血栓性疾病提供了部分实验依据。抗衰老提高免疫力:女贞子煎剂可使小鼠免疫器官胸腺、脾脏重量增加;明显提高小鼠血清溶血素抗体活性,对小鼠脾淋巴细胞产生白介素-2的影响具有双向调节作用。女贞子具有显著的免疫增强作用,清除自由基从而抗衰老。应用女贞子防治:心血管疾病、冠心病、高脂血症、糖尿病、血小板减少症、白细胞减少症,慢性肾炎、慢性支气管炎、顽固性失眠、慢性苯中毒、肿瘤、营养不良、免疫功能低下症、脂溢性皮炎
桑葚滋阴养血药;生津药;润肠药。补血滋阴,生津润燥。用于眩晕耳鸣,心悸失眠,须发早白,津伤口渴,内热消渴,血虚便秘。补肝,益肾,熄风,滋液。治肝肾阴亏,消渴,便秘,目暗,耳鸣,瘰疬,关节不利。既可入食,又可入药,中医认为桑葚味甘酸,性微寒,入心、肝、肾经,为滋补强壮、养心益智佳果。具有补血滋阴,生津止渴,润肠燥等功效,主治阴血不足而致的头晕目眩,耳鸣心悸,烦躁失眠,腰膝酸软,须发早白,消渴口干,大便干结等症。
桑白皮:桑白皮的醇提取液5~6mg/kg,对麻醉兔、犬十二指肠给药可使动物血压明显而持久的下降。而对实验性肾性高血压的动物20g/kg口服,亦能产生明显的降压作用。切断两侧迷走神经或于第5~6颈椎部位切断脊髓,其降压作用不变。桑白皮用乙醚、热水或温甲醇的提取液,对兔皮下注射1g(生药)/kg时,可使血压下降2~3.3kPa。从桑白皮中提得一种物质[熔点(分解)为144℃],给家兔静注10mg/kg,血压立即显著下降,切断颈迷走神经或颈椎,此作用仍存在,故推断提取物中可能是乙酰胆碱样物质。桑白皮提取物能抑制离体蛙心、兴奋兔离体肠管,而降低血压作用可被阿托品对抗。提示此种降压抑制,可能是抑制了血管运动中枢而出现的,降压同时对肾血流量似有增加。从桑白皮中分离出的桑根酮静注家兔,即能显著降压,环桑皮素、桑皮呋喃C等都有降压作用。
具体实施例1:
早春、晚秋采挖枸杞根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟。
再将其余原料桑寄生,五加皮,桑白皮,山茱萸,茯苓,丹参,川芎,蔓荆子,制首乌,仙茅,桑葚,女贞子,白芍,虎杖,半枝莲,提取,制成膏剂、颗粒剂或粉剂。
将制备好的地骨皮与提取物的膏剂、颗粒剂或粉剂混合,紫外线杀菌消毒装袋。
具体实施例2:
早春、晚秋采挖枸杞根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟,大约5000g。
再取其他原料桑寄生1500g,五加皮1500g,桑白皮1500g,山茱萸1500g,茯苓1500g,丹参1500g,川芎1500g,蔓荆子1500g,制首乌1500g,仙茅1500g,桑葚1500g,女贞子1500g,白芍1500g,虎杖1500g,半枝莲1500g,加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.5g生药量,然后加蜂蜜调和,制成颗粒剂,混合制备好的地骨皮,紫外线灭菌,包装即得。
具体实施例3:
早春、晚秋采挖枸杞根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟,大约4000g。再取其他原料桑寄生1200g,五加皮1200g,桑白皮1300g,山茱萸1100g,茯苓1100g,丹参1200g,川芎1200g,蔓荆子1100g,制首乌1200g,仙茅1100g,桑葚1200g,女贞子1100g,白芍1300g,虎杖1200g,半枝莲1100g,取原料药洗净晾干,于70℃烘箱中,烘1-3h,取出置于干燥箱内冷却,用粉碎机粉碎过80-100目筛。将过筛的颗粒物浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,粉末置于70-90%乙醇中浸泡1-2小时,在水浴锅内加热到60℃-70℃,浸提2h,每10min搅拌一次,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状。然后加蜂蜜调和,制成颗粒剂,混合制备好的地骨皮,紫外线灭菌,包装即得。
具体实施例4:
早春、晚秋采挖枸杞根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟,大约3500g。将炒好的地骨皮泡入乙醇中1-2天后,加热提取2次,每次1-2小时,去上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成组分1;将其余原料药材混合,桑寄生1200g,五加皮1200g,桑白皮1300g,山茱萸1100g,茯苓1100g,丹参1200g,川芎1200g,蔓荆子1100g,制首乌1200g,仙茅1100g,桑葚1200g,女贞子1100g,白芍1300g,虎杖1200g,半枝莲1100g,切碎过100~120目筛,过筛后细粉备用,粗颗粒放入耐酸碱浸渍锅,在室温下,与70度以上乙醇一起浸渍3~7天,然后加热回流提取2次,每次1~2小时,将2次提取液合并静置,过滤,分离后取滤液;用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2;将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至80℃时相对密度为1.60的浸膏,浓缩后的膏剂加蜂胶或糊精调和制粒,紫外线消毒杀菌后装瓶。
药理学毒性试验
实验例1:本发明急性毒性试验
一、试验材料:动物:昆明种小鼠,体重18-25g,雌雄各半,山东大学生物试验室育种。药物:本发明(所有原材料混合煎煮2次,合并过滤,取药液)含0.0365mg/ml。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将本发明加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将本发明加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
实验例2:急性毒性及长期毒性的试验结果
急性毒性试验:通过小白鼠一次性灌胃给予本发明,最高浓度35%,最大灌胃容量0.4ml/10g,剂量14g/kg(每g药粉相当于10g生药),连续观察7天,未发现任何毒性反应,因浓度和剂量无法增加,故未能测出该药的LD50。最大耐受量测定:以最高浓度,最大灌胃容量,小白鼠灌胃给药3次,间隔5小时,然后连续观察7天,无一例死亡。药粉剂量为>42g/kg.日(每g药粉相当于10g生药),按公斤体重计算相当于成人临床日用量的420倍。
长期毒性试验:为观察长期用药是否产生毒性反应,分别给予大鼠本发明饲服,按成人临床日用量的70倍和35倍(即7g/kg/日和3.5g/kg/日),连续给喂8周,未见大鼠的行为、进食、体重出现异常,与对照组比,血常规,肝肾功能,各种重要脏器均无异常改变,在所用药剂量范围内,未曾发现本发明的任何毒副反应。通过动物的急慢性毒性试验证实,本发明安全范围较大,是一种安全可靠的保健品。
药理学实验:
观察本发明对实验动物血糖血脂的影响。方法:采用四氧嘧啶所致的糖尿病小鼠模型,用链脲佐霉素(STZ)并给予高热量饮食的方法复制II型糖尿病大鼠模型,以本发明、格列吡嗪分别给予治疗,而后称其体重,测量血清甘油三酯、胆固醇、血清胰岛素含量及进行葡萄糖耐量试验。结果:本发明明显降低糖尿病小鼠的血糖,减轻2型糖尿病大鼠的体重,阻止肥胖的发生。同时也能降低外周血清胰岛素水平,改善胰岛素抵抗这一2型糖尿病普遍存在的显著特征。结论:本发明具有明显的降糖降脂作用。
1材料和方法
1.1实验动物:Wister大鼠,雄性,体重200~250g;昆明种小鼠(雌雄兼用)每只18~20g左右,以上动物均为山东农学院动物中心提供。
1.2高热量饲料:由基础饲料加蔗糖、炼猪油混合而成,其总热量为20.08KJ/g(蛋白质15%、碳水化合物51%、脂肪25%)。
1.3药物和试剂:地骨皮35g,桑寄生12g,五加皮13g,桑白皮11g,山茱萸12g,茯苓12g,丹参11g,川芎12g,蔓荆子11g,制首乌12g,仙茅11g,桑葚12g,女贞子12g,白芍12g,虎杖11g,半枝莲12g,(购自山东中医学院保康医院门诊部),水煎醇沉后制成100%的药液备用。STZ为Sigma公司产品,批号:S0130;四氧嘧啶为Sigma公司产品,临用时以0.1mmol/L、pH4.2的柠檬酸一柠檬酸钠缓冲液配成1%的溶液;格列吡嗪片为海南金晓制药有限公司产品,批号:001213;血糖试剂盒、胆固醇试剂盒、甘油三酯试剂盒和血清胰岛素放免试剂盒均购自北京中生生物工程高技术公司。
1.4实验仪器:半自动生化分析仪:EPPENDORF-F6124型,德国;放射免疫测定仪:海军医疗设备总厂,中国。
1.5实验模型的制备:糖尿病高脂血症大鼠模型的制备:大鼠尾静脉快速注射STZ30mg/kg,喂以基础饲料,自由饮水,2周后尾静脉采血,进行葡萄糖耐量试验;挑选葡萄糖耐量异常大鼠喂以人工合成高热量饲料,持续喂养2个月。
糖尿病小鼠模型的制备:取昆明种小鼠,禁食10h,而后尾静脉注射四氧嘧啶100mg/kg,于72h后从小鼠眼眶取血,测血糖值;血糖值在11.0mmol/L以上者为造模成功,用于以后实验。
1_6观测指标与方法:体重:用Sartorius(德国)生产的电子秤称量。血糖:GOD-PAP法。血清甘油三酯:GPO-PAP法。血清胆固醇:CHO13-PAP法。以上3项指标均按药盒说明书操作,用德国产EPPENDORF-F6124型半自动生化分析仪测定。血清胰岛素用放免法,按说明书进行操作。
1.7数据处理:实验数据以-X±S表示,数据统计有效性采用t检验。
2实验结果
2.1本发明对正常小鼠血糖的影响:取小鼠30只,随机分3组:正常组、本发明组(5g/kg)和格列吡嗪组(1.3mg/kg)。每日上午灌胃给药,连续14d,于末次给药后禁食6h,于小鼠眼眶取血测血糖。结果表明,本发明对正常小鼠没有降血糖作用(P>0.05)。见表1。
表1 本发明对正常小鼠血糖的影响。(x±s)
| 组别 | N | 血糖mmol/L |
| 正常组 | 10 | 6.21±1.34 |
| 本发明组 | 10 | 5.34±1.16* |
| 格列吡嗪组 | 10 | 5.59±0.86** |
注:与正常组比较,*P>0.05,**P<0.01
2.2本发明对四氧嘧啶性糖尿病小鼠的影响:取正常小鼠10只,测其血糖值,用常规饲料喂养。另取成模小鼠50只,随机分为5组,即模型组、本发明组(高、中、低剂量组)和格列吡嗪组,连续给药14d。于末次给药后1h,将以上6组小鼠眼眶取血,测其血糖值。
结果表明,给与四氧嘧啶后,模型组较正常对照组小鼠血糖水平显著升高,至实验第14d其血糖仍维持在较高水平。本发明组血糖水平明显低于模型组,表明本发明可使四氧嘧啶糖尿病小鼠血糖降低(P<0.05),但仍高于正常对照组(P<0.05)。见表2。
表2 本发明对四氧嘧啶性糖尿病小鼠血糖的影响(x±s)
注:与正常组比较,*P<0.05,***P<0.01;与模型组比较,ΔP<0.05,ΔΔΔP<0.001
2.3本发明对糖尿病高脂血症大鼠的作用
2.3.1本发明对糖尿病高脂血症大鼠体重的影响:分组、给药同上,日给药1次,连续灌胃30天。实验期间动物饮水及饲料不加限制。
结果表明,模型组体重明显高于正常组(P<0.01),本发明组和格列吡嗪组体重明显低于模型组(P<0.01,P<0.05),本发明组和格列吡嗪组与正常组比较无差异(P>0.05,P>0.05)。说明本发明有一定的降低模型大鼠体重的作用。见表3。
表3 本发明对糖尿病高脂血症大鼠体重的影响(x±s)
| 组别 | N | 药量 | 体重(g) |
| 正常组 | 10 | —— | 246.00±15.84 |
| 模型组 | 10 | —— | 316.5±18.34** |
| 本发明组(低) | 10 | 5g/kg | 285.65±15.31Δ |
| 本发明组(中) | 10 | 10g/kg | 280.26±18.34ΔΔ |
| 本发明组(高) | 10 | 15g/kg | 270.45±17.43ΔΔ |
| 格列吡嗪组 | 10 | 1.3mg/kg | 272.67±19.65Δ |
注:与正常组比较,**P<0.01;与模型组比较ΔP<0.05,ΔΔP<0.01
2.3.2本发明对糖尿病高脂血症大鼠葡萄糖耐量的影响:分组与给药同上。大鼠禁食8h,腹腔内注射1.11mol/L葡萄糖溶液2g/kg,断尾取血测即刻(0)、30、60和120min血糖值。经t检验,模型组糖耐量异常(即刻与120min比较,P<0.05),经方差分析,该组30、60和120min血糖明显高于正常组(P<0.001,P<0.01和P<0.05)。本发明组30和60min显著高于正常组(P<0.001,P<0.01),但也明显低于模型组(P<0.01,P<0.05),且糖耐量正常(即刻与120min比较,P>0.05)。见表4.
表4 本发明对糖尿病高脂血症大鼠萄萄糖耐量的影响(x±s)
注:与正常组比较,*P<0.05,**P<0.01,***P<0.001;与模型组比较,ΔP<0.05,ΔΔP<0.01;与本组即刻比较,▲P<0.05。
2.3.3本发明对糖尿病高脂血症大鼠血清甘油三酯、胆固醇的影响:分组、给药同上。结果表明,模型组血清甘油三酯、胆固醇与正常组比较明显升高(P<0.001,P<0.001);两地汤各组均高于正常组(P<0.01,P<0.001),但明显低于模型组(P<0.001,P<0.001);格列吡嗪均明显高于对照组(P<0.001,P<0.001),但与模型组比较无明显差异(P>0.05,P>0.05)。说明本发明有一定的降低血清甘油三酯、胆固醇的作用,列吡嗪却没有此作用。见表5。
表5 本发明对糖尿病高脂血症大鼠血清甘油三酯、胆固醇的影响(x±s)
注:与正常组比较,*P<0.01,**P<0.001;与模型组比较,ΔP<0.001
2.3.4本发明对糖尿病高脂血症大鼠血清胰岛素的影响:分组、给药同上。结果表明,模型组血清胰岛素明显高于正常组(P<0.01);本发明各组和格列吡嗪组明显低于模型组(P<0.05,P<0.05),但也高于正常组(P<0.05,P<0.05)。说明本发明有一定的降低血清胰岛素的作用,此作用与格列吡嗪相似。见表6。
表6 本发明对糖尿病高脂血症大鼠血清胰岛素的影响(x±s)
| 组别 | N | 药量 | 胰岛素μIU/ml |
| 正常组 | 10 | —— | 22.84±2.42 |
| 模型组 | 10 | —— | 28.11±2.41** |
| 本发明组(低) | 10 | 5g/kg | 25.58±1.33*Δ |
| 本发明组(低) | 10 | 10g/kg | 24.24±1.64*Δ |
| 本发明组(低) | 10 | 15g/kg | 23.12±1.32*Δ |
| 格列吡嗪组 | 10 | 1.3mg/kg | 24.06±1.48*Δ |
注:与正常组比较,*P<0.01,**P<0.001;与模型组比较,ΔP<0.005
实验表明本发明能明显降低糖尿病小鼠血糖,但对正常动物的血糖水平没有影响,其降糖机理与直接刺激胰岛B细胞分泌胰岛素的作用无关,可能与其减轻胰岛B细胞的损伤,恢复胰岛受损的结构和功能以及通过对糖代谢的调节有关。同时也能降低外周血清胰岛素水平,改善胰岛素抵抗这一2型糖尿病普遍存在的特征。此外,本发明能够减轻2型糖尿病大鼠的体重,抑阻肥胖的发生,使体重可以控制在正常的范围内,降低了糖尿病所伴发的高脂血症。
地骨皮的主要成分为:含桂皮酸和多量酚类物质,甜菜碱,尚分离到B一谷甾醇、亚油酸及地骨皮甲素等。正是这些有效的成分可降低“三高”(高血脂、高血压、高血糖)。降血糖过程主要是对胰岛B细胞分泌胰岛素有促进作用。现代药理学也证实,其煎剂口服可使血糖降低,并呈现降低血脂作用。还能降低血压、减慢心律,大剂量可导致房室传导阻滞。现代中医临床也广泛的应用地骨皮治疗糖尿病,水煎代茶频饮,有一定的降糖及降脂效果;如将地骨皮制成4%浓度的水煎液,适当加点白糖,对降血压也有较好的疗效。现代中药药理学已证实本发明的桑寄生、茯苓、桑白皮有一定的降糖或降脂作用,虽然本发明药效学的成分目前尚不清楚,但本发明的降糖降脂作用不容忽视,有较好的物质基础。本方对糖尿病发生的实质-阴虚的改善作用确实,从消渴病阴亏燥热的病机到滋阴清热的辨证施治与中医药理论比较相符,其作用机制有待今后深入研究。
近年来,随着人们生活水平的不断提高,糖尿病、冠心病等疾病发病率日益增加。中草药作用稳定,副作用少,研究具有降糖降脂作用的中草药,能为临床上治疗糖尿病、高脂血症提供更多的方法。
Claims (10)
1.一种降脂降糖的地骨皮保健茶,其特征在于,所述地骨皮保健茶包括以下重量份数的原料:地骨皮10~50份,桑寄生10~20份,五加皮10~20份,桑白皮10~20份,山茱萸10~20份,茯苓10~20份,丹参10~20份,川芎10~20份,蔓荆子10~20份,制首乌10~20份,仙茅10~20份,桑葚10~20份,女贞子10~20份,白芍10~20份,虎杖10~20份,半枝莲10~20份。
2.根据权利要求1所述降脂降糖的地骨皮保健茶,其特征在于,所述地骨皮保健茶中各种原料的重量份数为:地骨皮10~30份,桑寄生10~15份,五加皮10~15份,桑白皮10~15份,山茱萸10~15份,茯苓10~15份,丹参10~15份,川芎10~15份,蔓荆子10~20份,制首乌10~20份,仙茅10~20份,桑葚10~20份,女贞子10~20份,白芍10~20份,虎杖10~20份,半枝莲10~20份。
3.根据权利要求1所述降脂降糖的地骨皮保健茶,其特征在于,所述地骨皮保健茶中各种原料的重量份数为:地骨皮10~40份,桑寄生10~20份,五加皮10~20份,桑白皮10~20份,山茱萸10~20份,茯苓10~20份,丹参10~20份,川芎10~20份,蔓荆子10~15份,制首乌10~15份,仙茅10~15份,桑葚10~15份,女贞子10~15份,白芍10~15份,虎杖10~15份,半枝莲10~15份。
4.一种如权利要求1~3项任一项所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述地骨皮保健茶的制备步骤包括以下方面:
a.地骨皮的制备;
b.将所述其余原料浸泡乙醇中加热提取成浸膏;
c.再将其余原料提取的浸膏浓缩成颗粒剂、粉剂或膏剂;
d.将浓缩的颗粒剂、粉剂或膏剂与制备好的地骨皮混合,灭菌制备成保健茶剂。
5.根据权利要求4所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述步骤a中,早春、晚秋采挖枸杞树根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟。
6.根据权利要求4所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述步骤b中,取其余原料洗净去杂,加入占其质量5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用。
7.根据权利要求4所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述步骤c中,将上述步骤得到的浸膏置入双效真空浓缩器中,浓缩至80℃时相对密度为1.50的浸膏,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,浸膏再置入双效真空浓缩器中,浓缩至每1ml含0.5g生药量;浓缩后的膏剂加蜂蜜调和制成颗粒剂;或直接干燥制成粉剂。
8.根据权利要求4所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述步骤d中,将制好的地骨皮与提炼的其他原料的颗粒剂、粉剂或膏剂混合,经紫外线消毒杀菌后装袋。
9.一种如权利要求1~3中任一项所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,其制备步骤还可以为:
a.地骨皮的制备,作为组分1;
b.将所述其余原料药提取作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂胶或糊精调和制粒,紫外线消毒杀菌后装瓶。
10.根据权利要求9所述降脂降糖的地骨皮保健茶的制备方法,其特征在于,所述步骤a中,早春、晚秋采挖枸杞树根部,洗净泥土,将鲜根切成5-10厘米长的小段,再纵剖至木质部,置蒸笼中略加热,待皮易剥离时,取出剥下皮部,晒干,以块大、肉厚、无木心与杂质者为佳,放入铁锅中文火翻炒10-15分钟;将炒好的地骨皮泡入乙醇中1-2天后,加热提取2次,每次1-2小时,去上清液,合并提取液,100-110目滤过,再经截流分子量为6000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用,成组分1;所述步骤b中,将其余原料药材混合,将其余原料放入占其质量10倍量的乙醇中浸泡24小时以上,加热回流提取2次,每次1~2小时,将2次提取液合并静置;再将上述乙醇提取过的药材的药渣加占其质量10倍量的水加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,作为组分2;所述步骤c中,混合组分1和组分2,回收乙醇后减压放入浓缩器中浓缩,将所得浓缩液调整比重到1.46,减压,浓缩后的膏剂加蜂胶或糊精调和制粒,紫外线消毒杀菌后装瓶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410425687.3A CN104206595A (zh) | 2014-08-27 | 2014-08-27 | 一种降脂降糖的地骨皮保健茶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410425687.3A CN104206595A (zh) | 2014-08-27 | 2014-08-27 | 一种降脂降糖的地骨皮保健茶及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104206595A true CN104206595A (zh) | 2014-12-17 |
Family
ID=52088813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410425687.3A Pending CN104206595A (zh) | 2014-08-27 | 2014-08-27 | 一种降脂降糖的地骨皮保健茶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104206595A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104222424A (zh) * | 2014-08-28 | 2014-12-24 | 青岛恒波仪器有限公司 | 一种降脂降糖的地骨皮保健茶及其制备方法 |
| CN104904964A (zh) * | 2015-07-07 | 2015-09-16 | 青岛恒波仪器有限公司 | 一种降糖降脂的罗布麻叶保健茶及其制备方法 |
| CN105851362A (zh) * | 2016-03-30 | 2016-08-17 | 黄山树德堂食品饮料有限公司 | 一种养血益肾、清肝明目的菊花保健茶及其制备方法 |
| CN106954721A (zh) * | 2017-05-09 | 2017-07-18 | 福建省园仔山茶业有限责任公司 | 一种养生保健茶及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103749819A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种降糖降脂的山茱萸保健茶及其制备方法 |
| CN103749822A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种女贞子降压降脂保健茶及其制备方法 |
-
2014
- 2014-08-27 CN CN201410425687.3A patent/CN104206595A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103749819A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种降糖降脂的山茱萸保健茶及其制备方法 |
| CN103749822A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种女贞子降压降脂保健茶及其制备方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104222424A (zh) * | 2014-08-28 | 2014-12-24 | 青岛恒波仪器有限公司 | 一种降脂降糖的地骨皮保健茶及其制备方法 |
| CN104904964A (zh) * | 2015-07-07 | 2015-09-16 | 青岛恒波仪器有限公司 | 一种降糖降脂的罗布麻叶保健茶及其制备方法 |
| CN105851362A (zh) * | 2016-03-30 | 2016-08-17 | 黄山树德堂食品饮料有限公司 | 一种养血益肾、清肝明目的菊花保健茶及其制备方法 |
| CN106954721A (zh) * | 2017-05-09 | 2017-07-18 | 福建省园仔山茶业有限责任公司 | 一种养生保健茶及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103734428B (zh) | 一种提高免疫力的女贞子保健茶及其制备方法 | |
| CN103749822B (zh) | 一种女贞子降压降脂保健茶及其制备方法 | |
| CN103734426B (zh) | 一种提高免疫力的山茱萸保健茶及其制备方法 | |
| CN104208302A (zh) | 一种降血脂的金樱子保健口服液及其制备方法 | |
| CN103027155A (zh) | 一种桑叶降脂降压保健茶及其制备方法 | |
| CN103719492A (zh) | 一种绞股蓝护肝养肝保健茶及其制备方法 | |
| CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
| CN104305205B (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
| CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
| CN104365943A (zh) | 一种降糖降脂的槐角茶及其制备方法 | |
| CN103749824B (zh) | 一种绞股蓝降糖降压保健茶及其制备方法 | |
| CN103735835A (zh) | 一种治疗少白头的中药制剂及其制备方法 | |
| CN103719495B (zh) | 一种牛蒡子降糖降脂保健茶及其制备方法 | |
| CN106177053A (zh) | 一种包含青钱柳叶和陈皮的降血糖保健组合物 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
| CN104304602A (zh) | 一种软化血管的槐角茶及其制备方法 | |
| CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
| CN104223297A (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
| CN104473154A (zh) | 一种延缓衰老的桑葚保健口服液及其制备方法 | |
| CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
| CN105211441A (zh) | 一种降压降脂的丹参叶保健茶及其制备方法 | |
| CN105455125A (zh) | 一种提高免疫力的龙眼肉口服液及其制备方法 | |
| CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
| CN104397282A (zh) | 一种安神补脑的刺五加保健茶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141217 |